1. Home
  2. VHC vs CTSO Comparison

VHC vs CTSO Comparison

Compare VHC & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirnetX Holding Corp

VHC

VirnetX Holding Corp

HOLD

Current Price

$20.24

Market Cap

79.2M

Sector

Miscellaneous

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.71

Market Cap

45.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VHC
CTSO
Founded
2005
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
79.2M
45.9M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
VHC
CTSO
Price
$20.24
$0.71
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
14.9K
119.9K
Earning Date
11-14-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$106,000.00
$36,979,520.00
Revenue This Year
N/A
$9.51
Revenue Next Year
N/A
$24.40
P/E Ratio
N/A
N/A
Revenue Growth
2020.00
23.89
52 Week Low
$3.68
$0.60
52 Week High
$29.00
$1.61

Technical Indicators

Market Signals
Indicator
VHC
CTSO
Relative Strength Index (RSI) 47.94 45.48
Support Level $18.21 $0.66
Resistance Level $22.27 $0.76
Average True Range (ATR) 1.97 0.07
MACD -0.18 -0.00
Stochastic Oscillator 42.30 39.10

Price Performance

Historical Comparison
VHC
CTSO

About VHC VirnetX Holding Corp

VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: